Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
Cabaletta Bio presented new Phase 1/2 data for rese-cel at EULAR 2026, showing 83% of dermatomyositis patients achieved durable, immunomodulator-free responses lasting up to 1.5 years. In systemic sclerosis, 83% of patients achieved significant skin/lung improvement off immunomodulators, supporting a planned registrational study initiation in 4Q26.
Key figures
- Drug Name
- rese-cel
- Phase Of Trial
- Phase 1/2
- Ssc patients
- 15
- Icans none sle
- 94%
- Icans none ssc
- 93%
- Lupus patients
- 20
- Dm response rate
- 83%
- Sle im free rate
- 83%
- Dm patients total
- 6
- Myositis patients
- 17
- Ssc rcriss25 rate
- 83%
- Ssc rcriss50 rate
- 67%
- Asys response rate
- 75%
- Sle remission rate
- 75%
- Sle total patients
- 18
- Ssc rcriss25 total
- 6
- Ssc rcriss50 total
- 6
- Asys patients total
- 4
- Icans none myositis
- 100%
- Sle remission total
- 8
- Sle im free patients
- 15
- Ssc rcriss25 patients
- 5
- Ssc rcriss50 patients
- 4
- Crs grade1 or none sle
- 94%
- Crs grade1 or none ssc
- 87%
- Dm patients responding
- 5
- Sle remission patients
- 6
- Asys patients responding
- 3
- Total evaluable patients
- 52
- Ssc fvc improvement median
- 7.5%
- Crs grade1 or none myositis
- 100%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.